Search

Your search keyword '"Lintzeris N"' showing total 58 results

Search Constraints

Start Over You searched for: Author "Lintzeris N" Remove constraint Author: "Lintzeris N" Topic buprenorphine Remove constraint Topic: buprenorphine
58 results on '"Lintzeris N"'

Search Results

1. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.

2. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.

4. The impact of changes in opioid dependency treatment upon COVID-19 transmission in Sydney, Australia: a retrospective longitudinal observational study.

5. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.

6. Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia.

7. Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine.

8. Strategies for Transfer From Methadone to Buprenorphine for Treatment of Opioid Use Disorders and Associated Outcomes: A Systematic Review.

9. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

10. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.

11. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.

12. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.

13. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine.

14. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.

15. Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.

16. Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study.

17. Effects of ascending buprenorphine doses on measures of experimental pain: A pilot study.

18. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.

19. Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment.

20. Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines.

21. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment.

22. Opioid agonist treatment for pharmaceutical opioid dependent people.

23. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.

24. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?

25. Buprenorphine diversion and misuse in outpatient practice.

26. The diversion and injection of a buprenorphine-naloxone soluble film formulation.

27. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.

28. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.

29. Methadone and buprenorphine prescribing patterns of Victorian general practitioners: their first 5 years after authorisation.

30. "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.

31. Benzodiazepines, methadone and buprenorphine: interactions and clinical management.

32. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.

34. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.

35. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.

36. Fast-tracking implementation through trial design: the case of buprenorphine treatment in Victoria.

38. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients.

39. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

40. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients.

41. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial.

42. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions.

43. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial.

44. Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom-triggered dose titration study.

45. Training primary health care professionals to provide buprenorphine and LAAM treatment.

46. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal.

47. Buprenorphine dosing regime in the management of out-patient heroin withdrawal.

48. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose.

49. A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia

50. Buprenorphine may be more effective than clonidine and other symptomatic medications for short term ambulatory heroin withdrawal.

Catalog

Books, media, physical & digital resources